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ON THE COVER:  
For David Ferriday, diagnosed 
with stage III colon cancer,  
a new immunotherapy clinical 
trial at Providence was his 
game-changer. See Page 4.
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We are pleased to share with you our highlights from 
an exciting year in cancer medicine and research. 2017 
marked the 30-year anniversary of our institute. From 
our humble beginnings, our team has grown to more 
than 130 investigators and research personnel, includ-
ing 19 faculty members recognized globally for their 
pioneering contributions to cancer immunotherapy. 
With the passing of another year, we find yet again 
that a novel immunotherapy – adoptive cell therapy – 
is named the Advance of the Year by the American 
Society of Clinical Oncology. Through the development 
of our adoptive cell therapy and genomics programs, 
we are poised to offer genome-guided, personalized 
immunotherapies to our patients. 
Another important advancement of last year came 
with the first approval by the Food and Drug 
Administration for a cancer therapy based not on 
tumor type or location, but on a shared genetic profile. 
This immunotherapy – from which an estimated 
60,000 cancer patients stand to benefit each year – 
may represent a new standard of care, and we are 
proud of our contributions to the revolutionary clinical 
trial which prompted the accelerated FDA approval.
2017 was also a year of transformation for Providence 
Cancer Center brought about by philanthropic 
WALTER J. URBA, M.D., PH.D.
Member, director and endowed chair of Cancer Research,
Earle A. Chiles Research Institute,
a division of Providence Cancer Institute
at the Robert W. Franz Cancer Center
MESSAGE FROM THE DIRECTOR
Welcome to our 2017 Year in Review, the accomplishments  
report of the Earle A. Chiles Research Institute. 
support. In tribute to our longtime friend and 
benefactor, the center was renamed the Robert W. 
Franz Cancer Center. As a former board member of 
Providence Portland Medical Foundation, Bob gave 
generously of his time and resources to support our 
growing cancer program. Together with his sister,  
Elsie Franz Finley, he was instrumental to our evolution 
as a worldwide leader in cancer immunotherapy. 
The Robert W. Franz Cancer Center is now part of 
Providence Cancer Institute – a regional ministry 
supporting the comprehensive cancer services of 
Providence Health & Services throughout Oregon. And 
as we plan for the future, construction is underway to 
ensure we are equipped for state-of-the-art care and 
translational research for many years to come.
When I reflect on our journey over the past three 
decades, I am filled with gratitude for the many 
friends and supporters who have joined us along the 
way. And memories of those who have passed away 
remind us that our job is not done. 
Cancer does not quit, and neither do we. I invite you 
to join us on our quest for a cancer-free future. With 
your support, together we can finish cancer.
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NEW ADDITIONS AND NOTEWORTHY ACHIEVEMENTS
New standard of care
A phase II clinical trial drew 
national headlines in 2017 when 
66 of 86 patients with cancer saw 
their tumors shrink or stabilize in 
response to immunotherapy. For 
18 of the patients who responded 
to therapy, their tumors vanished 
completely. With nearly 77 percent 
of patients benefiting from disease 
control, the study’s novel design and notable responses in 
patients with multiple tumor types captured the interest 
of researchers across the country. 
As reported in Science and The New York Times, 
study investigators found evidence that a checkpoint 
immunotherapy was effective in treating patients whose 
cancers shared a distinct genetic abnormality known 
as mismatch repair deficiency – a defect in the ability 
to repair damaged DNA, leading to the first instance 
of approval by the Food and Drug Administration for a 
cancer treatment based on genetic profile rather than 
tumor type or origin in the body. 
The study, which is ongoing, is led by Johns Hopkins 
University in collaboration with six institutions across 
the United States, including the Robert W. Franz Cancer 
Center. Todd S. Crocenzi, M.D., associate member and 
director of Gastrointestinal Oncology Research, was the 
second investigator to enroll patients to the study.  
“These results will likely establish a new standard of 
care, with the potential for up to 60,000 cancer patients 
annually to benefit from this treatment approach,” 
said Dr. Crocenzi. Learn more on Page 24.
Immuno-Histology Core
The application of immunohistochemistry to preclinical 
and clinical research is critical to elucidating the 
mechanisms of cancer immunotherapy. At the forefront 
of this technology, Zhaoyu Sun, Ph.D., manager, 
Immuno-Histology Core, advises our investigators on 
imaging techniques to accomplish their research goals. 
With expertise in immunohistology, quantitative image 
analysis and multiplex immunofluorescence staining, 
she oversees the incorporation of new antibodies for 
investigation, the evaluation of new methods and 
techniques, and quality control. Established in 2017, 
the core is one of two components of the Immune 
Monitoring Laboratory directed by Associate Member 
William L. Redmond, Ph.D. Learn more on Page 38. 
These results will likely establish a new 
standard of care, with the potential for 
up to 60,000 cancer patients annually to 
benefit from this treatment approach.
From left, Immuno-Histology 
Core, Antitumor T-cell Response 
Lab, and genomics team.  
At right, Todd S. Crocenzi, M.D.
Adoptive cell therapy lab 
A sought-after recruit from the 
National Cancer Institute, Eric Tran, 
Ph.D., assistant member, Antitumor 
T-cell Response Laboratory, joined 
our faculty in 2017 to lead a 
laboratory devoted to adoptive cell 
therapy – a highly personalized 
immunotherapy approach 
celebrated as the Advance of the 
Year by the American Society of 
Clinical Oncology. Dr. Tran trained 
under renowned physician scientist 
Steven A. Rosenberg, M.D., Ph.D., 
chief of the NCI Surgery Branch, 
with whom he contributed to 
groundbreaking studies showing the effectiveness  
of this treatment strategy in patients with cancer.  
Learn more on Page 6.
Genomics expansion 
Precision oncology – personalized cancer care aided 
by genomic profiling – is a promising treatment 
strategy for patients with cancer. By analyzing the 
genetic profiles of patients’ individual tumors, clinicians 
may be able to predict which therapies will offer the 
greatest benefits. In 2017, we expanded our genomics 
program to complement our steadfast integration of 
genomics and immunotherapy. Computational and 
systems biologist Brady Bernard, Ph.D., and genomic 
scientist Brian Piening, Ph.D., join Carlo B. Bifulco, 
M.D., our director of Translational Molecular Pathology, 
in developing robust bioinformatics and genomics 
support for our investigators. Learn more on Page 26.
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Center of Hope Initiative
Donors did it! In 2013, 
Providence Foundations 
of Oregon launched the 
Center of Hope Initiative, 
a five-year, $65 million 
campaign to support 
services of Providence 
Cancer Institute throughout 
Oregon, including cancer 
research, patient care and 
operational priorities. In 
2017, we exceeded this 
goal ahead of schedule 
thanks to the generosity 
of donors. The initiative 
also strengthened our 
statewide partnerships with 
community organizations 
such as Safeway 
Albertsons, Portland 
General Electric, Providence 
Hood to Coast Relay,  
The Human Bean and 
Susan G. Komen.
Philanthropic support 
provides opportunity for 
growth and aids our sustainability. Gifts have strengthened our endowment, 
helping us recruit and retain more scientists and physicians. Plans are underway to 
expand our laboratory space and recruit investigators to lead new areas of cancer 
research and develop better therapies for patients with cancer.
Philanthropy was also instrumental in establishing Providence Guest House, a 
30-room housing facility opened in 2015 for patients and their families who come 
to Portland for care, and the 11-story expansion of cancer services and research 
in 2008. In 2017, this facility was renamed the Robert W. Franz Cancer Center to 
honor the single largest donor in Providence’s 142 years in Oregon. Learn more  
on Page 42.
Since our founding 30 years ago, we 
have helped advance both the science of 
cancer research and the standard of care 
for patients with cancer. From leading the global clinical trial of ipilimumab to 
launching Oregon’s first adoptive cell therapy lab for patients with epithelial 
cancers, our team has often been first in the world, or first in Oregon, to offer 
promising immunotherapies to patients with cancer. 
First in Oregon: Adoptive cell 
therapy for renal cancer
First globally: gene-modified 
vaccine + adoptive cell 
therapy for cancer
First in Oregon: sipuleucel-T 
for prostate cancer 
First globally: IL-21 for 
melanoma and renal cancer
First-in-human trial of anti-OX40
First-in-human trial of 
DRibble vaccine
First-in-human trial of SBRT + 
IL-2 for melanoma and renal 
cancer
First in Oregon: nivolumab 
for lung cancer 
First cancer immunotherapy, 
ipilimumab, approved by FDA
First globally: nivolumab + 
varlilumab for ovarian cancer 
First globally: nivolumab + 
lirilumab for head and neck 
cancer
First globally: modified 
Listeria vaccine for 
glioblastoma
First in Oregon: adoptive 
cell therapy lab for 
epithelial cancers
Earle A. Chiles Research 
Institute is founded 
1987
1995
2000
2006
2009
2012
2016
1994
1996
2004
2008
2011
2014
2017
First in Oregon: gene-modified 
vaccine for breast cancer
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WHEN DAVID FERRIDAY was working on the 11-story expansion of cancer 
services at Providence Portland Medical Center, he knew it was a project that could 
improve the lives of patients with cancer. What the Portland architect could not foresee 
was the personal significance it would have in his future. 
Ferriday’s employer, ZGF Architects, was engaged to lead the project. “It was early 
in my career. My role was limited to working on the inpatient floors with the interior 
designer,” said Ferriday. Opened in 2008, the tower’s award-winning design brings 
together cancer services and research, blending science and care for whole-person 
healing. From top to bottom, windows and skylights carry natural light to patient 
rooms and treatment spaces. “The public areas we provided outside of the patient rooms 
resemble living rooms, with nice views for patients and their families,” said Ferriday.  
“I can’t say I ever saw myself actually using them.” 
Routine screening 
A decade later, the 50-year-old husband and father of three underwent routine screening 
for colon cancer. An avid soccer player, Ferriday was in excellent health. When the 
colonoscopy revealed he had locally advanced cancer – stage III out of IV stages, he was 
stunned. Scans showed a 7-centimeter tumor wrapped around the inside of his colon 
and the invasion of nearby lymph nodes. 
Team Ferriday 
scores a win  
over cancer
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Although deaths from colorectal cancer have dropped 
steadily in recent decades, the disease remains one of the 
most lethal forms of cancer with fewer than 65 percent 
of patients surviving beyond five years. In 2017, an 
estimated 140,000 people were newly diagnosed, and 
more than 50,000 died from the disease. 
Ferriday’s primary care doctor referred him to 
Providence. A patient of the cancer center he once helped 
design, Ferriday met Medical Oncologist Anupama 
Acheson, M.D. She recommended the standard of care 
– chemotherapy and radiation as an attempt to shrink 
the tumor, followed by surgery. She also offered Ferriday 
the chance to participate in an immunotherapy clinical 
trial designed for patients like him, one that was available 
only at Providence. 
Putting cancer on the defensive
Physician scientist Kristina H. Young, M.D., Ph.D., 
has studied the effects of radiation and immunotherapy 
in colorectal cancer for more than a decade. After 
completing her medical and doctoral training in Oregon, 
the California native remained to pursue a fellowship in 
translational radiation oncology at the Earle A. Chiles 
Research Institute. In 2015, she joined its faculty to lead 
her own laboratory, making Portland her home. The 
following year she opened a phase II clinical trial testing 
galunisertib, an experimental immunotherapy given as 
an immune-boosting treatment prior to standard care, in 
patients with stage II or higher colorectal cancer. 
Galunisertib attacks cancer at multiple levels, from 
mechanisms involved in cancer cell growth to the 
reinforcement of patients’ anti-cancer immune responses. 
With standard care, a mere 10 percent of patients 
experience complete regression of their tumors. By 
adding galunisertib before radiation and chemotherapy, 
Dr. Young hoped the therapeutic trifecta would help 
more patients respond to therapy.
For Ferriday, the timing and location could not have 
been better. Dr. Young’s study is the first of its kind 
worldwide. Of 50 patients planned to participate, he was 
the second to enroll in the study. For two weeks, he took 
galunisertib daily in the form of a pill. Then he started 
radiation and chemotherapy. When it came time for 
surgery, he had completed four weeks of immunotherapy 
concurrent with chemoradiation, and experienced few 
side effects. 
A winning strategy
A defender on two Portland soccer teams, Ferriday 
continued playing matches throughout his treatments. 
“Physically it was hard, but it lifted my spirits immensely 
to be supported and to just be out there,” said Ferriday. 
Soccer enthusiasm runs deep in his household. His 
16-year-old daughter Addie plays central midfield for 
Lincoln High School, and another daughter rose to play 
in a semi-professional league. 
A native Oregonian, Ferriday grew up in Portland. 
Like his daughter, he attended Lincoln. That’s where he 
met Sally Tapanen through mutual friends. Years later, 
they reconnected at a school function, and married soon 
after. They were still newlyweds when they received his 
devastating diagnosis. “Thinking you’re going to lose 
your husband – it’s indescribable,” said Sally. “He tried  
to not let anything stop him.” 
With his family rallied around him, Ferriday 
underwent surgery in February 2017. And what his 
surgeons found was remarkable: his bulky tumor had 
shrunk five-fold to 1.4 centimeters, and all his lymph 
nodes were free of the disease. For Ferriday and his family, 
Dr. Young’s strategy was a success. Surgeons excised the 
remaining cancer and he was on his way to recovery.
Out on the field, he has a new 
passion to share. “Because my 
friends are all hitting the 50-year 
mark, I am really on them about 
getting screened for colon cancer,” 
said Ferriday. “I feel so fortunate 
to have health insurance through 
Providence. My care has been top 
notch at every step.” 
Learn more about Dr. Young and  
this study on Page 18. 
From left, Addie Ferriday, 
her dad David Ferriday and 
his wife Sally Tapanen.
“My care has been top 
notch at every step.”
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Antitumor T-cell 
Response Laboratory
As leader of the Antitumor T-cell Response 
Laboratory, Eric Tran, Ph.D., is investigating 
how adoptive cell therapy, or ACT, can be 
optimized to mediate cancer regression.
For Dr. Tran, 2017 was a year of opportunity.  
Recruited from the National Cancer Institute where  
he studied under cancer immunotherapy pioneer Steven 
A. Rosenberg, M.D., Ph.D., Dr. Tran joined the Earle 
A. Chiles Research Institute in January and began 
developing his lab. His newly created team, comprising  
a postdoctoral fellow and three research associates,  
is learning the specialized techniques of ACT he 
mastered while at the NCI. They are developing  
novel genome-guided T-cell therapies for patients  
with advanced cancers. 
GENOME-GUIDED ACT
A highly personalized form of immunotherapy, ACT 
harnesses the ability of the immune system to eliminate 
cancer through the collection, amplification and 
reinfusion of patients’ tumor-killing T cells. Dr. Tran 
seeks to augment this promising approach with the 
power of genomics. 
In his treatment strategy, patients’ tumor samples 
are obtained by surgical resection, and peripheral blood 
samples are also collected. T cells known to induce 
cancer regression are harvested from the samples, and 
genomic sequencing is performed to identify any 
DNA mutations in the tumors. Then Dr. Tran’s team 
analyzes the ability of the T cells to recognize the genetic 
Eric Tran, Ph.D., assistant member, Antitumor T-cell Response Laboratory
7mutations discovered by genomic sequencing. T cells 
with the greatest tumor-reactivity are expanded to vast 
quantities, typically billions, before they are reinfused to 
patients as highly specialized, anti-cancer armies. After 
infusion, patients may receive other immunotherapies, 
such as interleukin-2, which enhance the effectiveness of 
their T cells. 
To perform the genomic sequencing essential to this 
approach, Dr. Tran is aided by Carlo B. Bifulco, M.D., 
member and medical director, Molecular Genomics, and 
the bioinformatics team he oversees. A genetic mutation 
of particular interest to Dr. Tran is KRAS G12D, a 
mutation common to multiple cancers which bears 
potential as a therapeutic target of ACT, as reported by 
Drs. Rosenberg and Tran in the New England Journal of 
Medicine.
Dr. Tran will also partner with Brendan D. Curti, 
M.D., member and director, Cytokine and Adoptive 
Immunotherapy Program, to administer interleukin-2 
and other immunotherapies, and with hepatobiliary and 
pancreatic surgeon Pippa H. Newell, M.D., assistant 
member and medical director of Providence Liver Cancer 
Clinic, among other clinicians.
PROOF OF CONCEPT
NCI-supported research provided strong evidence that 
cancer patients’ responses to checkpoint immunotherapy 
are due in part to their tumor-reactive T cells. Clinical 
trials conducted by Dr. Tran and colleagues provided 
direct evidence that ACT can be effective in mediating 
regression of advanced cancers, with two reports of 
objective regression in patients with metastatic colorectal 
cancer and metastatic bile duct cancer. 
Despite recent progress, most cancer patients 
are not cured by current immunotherapy. “A major 
hurdle facing the field of cancer immunotherapy is 
to define mechanisms of immune resistance in the 
tumor microenvironment, and develop strategies to 
overcome them,” said Dr. Tran. As noted in his Nature 
Immunology article, the immunological targeting of 
cancer mutations may represent the final common 
pathway that results in cancer regression in response 
to a variety of cancer immunotherapies. “Effectively 
harnessing this pathway holds promise for improving 
clinical outcomes in patients with metastatic cancers,” 
said Dr. Tran.
In recognition of its potential to change treatment 
paradigms dramatically, ACT was selected as the 
Advance of the Year by the American Society of Clinical 
Oncology. And for the potential impact his research may 
have to advance cures for cancer, Dr. Tran was chosen 
among 15 promising early-career scientists by the Sidney 
Kimmel Foundation, which awarded him a two-year 
research scholar grant.
FUTURE CLINICAL TRIALS
In collaboration with his colleagues, Dr. Tran is 
developing clinical trials for patients whose cancers are 
predicted to recur within three years. These include 
pancreatic cancer and cholangiocarcinoma, cancers 
with some of the poorest prognoses. “We hope to offer 
patients this therapy as early as 2019,” said Dr. Tran.
PUBLICATIONS:
Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD, 
Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V, 
Fitzgerald PC, Rosenberg SA. An efficient single-cell 
RNA-seq approach to identify neoantigen-specific T 
cell receptors. Molecular Therapy: the Journal of the 
American Society of Gene Therapy. 2017; 26(2):379-89. 
PMID: 29174843.
Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala 
SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto 
TN, Merchant AS, Mehta GU, Chichura A, Shalem O, 
Tran E, Eil R, Sukumar M, Guijarro EP, Day C, Robbins P, 
Feldman S, Merlino G, Zhang F, Restifo NP. Identification 
of essential genes for cancer immunotherapy. Nature. 
2017; 548(7669):537-42. PMID: 28783722.
Rosenberg SA, Tran E, Robbins PF. T-cell transfer therapy 
targeting mutant KRAS. The New England Journal of 
Medicine. 2017; 376(7):e11. PMID: 28199803.
Tran E, Longo DL, Urba WJ. A milestone for CAR T 
cells. The New England Journal of Medicine. 2017; 
377(26):2593-6. PMID: 29226781.
Tran E, Robbins PF, Rosenberg SA. Final common 
pathway of human cancer immunotherapy: targeting 
random somatic mutations. Nature Immunology. 2017; 
18(3):255-62. PMID: 28198830.
A major hurdle facing the field of 
cancer immunotherapy is to define 
mechanisms of immune resistance 
in the tumor microenvironment, and 
develop strategies to overcome them.
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Basic Immunology 
Laboratory
Andrew D. Weinberg, Ph.D., is a leading 
expert in the immune-stimulating protein 
OX40, also known as CD134, and its antibody 
anti-OX40, an immunotherapy in development 
for patients with cancer. He is investigating the 
therapeutic effects of anti-OX40 therapy on a 
newly identified immune cell population.
Understanding why the immune system fails to eradicate 
tumors has been a goal of tumor immunologists for 
decades. One approach to this vexing problem is to 
identify tumor antigen-specific T cells in cancer patients, 
and enhance the cells’ ability to eliminate cancer.  
Dr. Weinberg’s team took up this strategy,  
and their findings may have important  
clinical implications. 
TUMOR ANTIGEN-SPECIFIC T CELLS
Antigens are proteins that alert the immune 
system to the presence of harmful entities such 
as viruses and tumors. CD8 T cells, a type of T 
lymphocyte, are capable of recognizing antigens 
produced by tumor cells – known as tumor 
antigens, and launching an anti-cancer immune 
response. However, when confronted with the immune-
suppressing forces of the tumor microenvironment, the  
T cells can be rendered ineffective. Identifying and 
boosting patients’ tumor antigen-specific T cells is an 
effective treatment strategy, made more effective by 
counteracting tumor immune suppression.
Andrew D. Weinberg, Ph.D., member and Judith Ann Hartmann Endowed Chair 
for the Laboratory of Basic Immunology
Dr. Weinberg’s team began by studying tumor-
infiltrating T lymphocytes, or TIL, collected from 
patients with solid tumors. “We reasoned that TIL  
would be a good starting point to identify ongoing 
tumor-specific T-cell responses,” said Dr. Weinberg.  
Their reasoning led to a remarkable discovery: a new 
subset of human CD8 T cells capable of recognizing  
and killing tumors.   
“Our studies revealed a novel population of CD8 
T cells that is highly enriched for tumor-reactivity in 
patients with solid tumors,” said Dr. Weinberg. “This 
discovery represents a significant advance in the ability 
to identify human tumor antigen-specific CD8 T cells 
among a diverse population of TIL.”
The novelty of their discovery lies in the cells’ unique 
characteristics: CD39 and CD103, two immune 
activation markers, were present on the cells’ surfaces, 
and the cells bear a gene expression signature which 
appears to keep them confined within the tumor 
microenvironment. These characteristics, among others, 
indicate the cells experience chronic stimulation. While 
they were capable of tumor antigen recognition, it seems 
their ability to halt cancer progression was impaired. 
Undeterred, Dr. Weinberg’s team dug deeper, looking 
for answers in the laboratory. By analyzing expanded 
T-cell subsets and a tumor cell line from the same 
patient, they compared the tumor-killing potency of the 
newly discovered cells to other T cells. In the lab, they 
demonstrated that only T cells endowed with the CD39\
CD103 phenotype killed cancer cells. “Based on these 
findings, focusing on this novel T-cell population may be 
a promising approach to boost immune-mediated tumor 
regression in patients with cancer,” said Dr. Weinberg. 
ANTI-OX40 THERAPY
Examining the same T-cell population, Dr. Weinberg’s 
team found that patients treated with anti-OX40 showed 
higher frequencies of T cells bearing the CD39\CD103 
phenotype than patients who received conventional 
therapies. They hypothesized that patients whose TIL 
contain higher frequencies of these cells will experience 
greater overall survival.
To test this premise, Dr. Weinberg’s laboratory is 
collaborating with R. Bryan Bell, M.D., D.D.S., FACS, 
and Rom S. Leidner, M.D., assistant members and  
co-directors, Providence Head and Neck Cancer 
Program, in a first-in-human clinical trial administering 
anti-OX40 to patients with head and neck cancer prior 
to surgery. By comparing patients’ tumor and blood 
samples before and after surgery, they seek to determine 
whether changes to these T cells following anti-OX40 
therapy are associated with improved survival.
“Our hope is that these studies will increase our 
understanding of how current immunotherapies affect 
tumor-reactive T cells at the cellular and molecular 
levels, and to guide the development of new therapies 
for patients that fail current treatments,” said Dr. 
Weinberg. “We envision this work will provide a partial 
road map for clinicians to treat cancer patients with 
immunotherapy for the next 10 to 20 years.”
PUBLICATIONS:
Bell RB, Feng Z, Bifulco CB, Leidner RS, Weinberg AD, 
Fox BA. Immunotherapy. In: Bell RB, Fernandes RP, 
Andersen PE, eds. Oral, Head and Neck Oncology and 
Reconstructive Surgery. China: Elsevier; 2017: 314-40.
Duhen R, Weinberg A. Agnostic antibodies to co-
stimulatory molecules. In: Butterfield LH, Kaufman HL, 
Marincola FM, eds. Cancer Immunotherapy: Principles 
and Practice. New York, NY: Demos Medical Publishing; 
2017: 331-54.We envision this work will provide a 
partial road map for clinicians to treat 
cancer patients with immunotherapy 
for the next 10 to 20 years.
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Cancer Immunobiology 
Laboratory
Hong-Ming Hu, Ph.D., is studying the role of 
autophagy – and antigen cross-presentation in 
particular – in therapeutic vaccines for patients 
with cancer.
Autophagy, the process by which cells recycle 
dysfunctional components and eliminate intracellular 
pathogens, is a long-standing focus of Dr. Hu’s research. 
From the outset, his laboratory has investigated the role 
of autophagy in cancer immunotherapy.
Therapeutic cancer vaccines have emerged as a viable 
immunotherapy strategy. Like other vaccines, cancer 
vaccines prompt an immediate immune response via 
the innate immune system, while also stimulating an 
adaptive immune response and long-term memory to 
prevent cancer recurrence. 
One approach to the development of cancer vaccines 
is to extract proteins from tumor cells, and prime the 
immune system to recognize the tumor proteins as 
foreign. Tumor proteins, also known as tumor antigens, 
can serve as targets of an effective immune response. 
However, appropriate antigen selection is essential to 
activating an effective immune response by vaccination. 
Similarly, the selection of vaccine adjuvants, a substance 
that enhances the body’s immune response to an antigen, 
is critical to eliciting cancer immunity. 
NANOPARTICLES AS VACCINE ADJUVANTS
Seeking to develop more effective cancer vaccines,  
Dr. Hu is evaluating the use of nanoparticles as vaccine Hong-Ming Hu, Ph.D., associate member, Cancer Immunobiology Laboratory
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adjuvants, and the function of nanoparticles in antigen 
cross-presentation. Key to inducing cancer immunity by 
vaccination, antigen cross-presentation entails the ability 
of certain antigen-presenting cells to acquire, process and 
present tumor antigens to CD8 T cells, converting naïve 
CD8 T cells into activated cancer-killers. 
As reported in Nanoscale Research Letters, Dr. Hu’s 
lab found that positively charged superparamagnetic iron 
oxide nanoparticles, or SPIO NPs, had a beneficial effect 
on antigen cross-presentation and CD8 T-cell activation 
compared to SPIO NPs with different chemistries. 
“Nanoparticles modified with different chemistries 
exhibit diverse biological properties and differ in their 
adjuvant potentials,” said Dr. Hu. “This will make us 
consider the design of effective and safe vaccine adjuvants 
more carefully in the future.”
UBIQUITIN ENRICHES TUMOR ANTIGENS
While Dr. Hu is testing the ability of nanoparticles to 
improve the immune responses of T cells, he is also 
evaluating methods for effective tumor antigen selection 
and extraction. One strategy is to analyze the role of the 
ubiquitin pathway in antigen cross-presentation. 
Ubiquitin, a small regulatory protein with autophagic 
functions, modifies other cellular proteins through a 
process known as ubiquitination, and tags mutated or 
defective proteins for degradation. When appended to 
proteins, ubiquitin can also act as an affinity tag, marking 
the proteins for purification without the need for prior 
identification of tumor antigens. 
His lab examined the function of purified 
ubiquitinated proteins derived from tumor cells, 
and their findings, reported in the Journal of 
Immunotherapy, shed light on the identification of 
tumor antigens by means of antigen cross-presentation. 
“Our studies establish that ubiquitinated proteins provide 
a relevant source of tumor antigens for activating an anti-
tumor immune response,” said Dr. Hu. “Ubiquitin can 
be used as an affinity tag to enrich for patients’ unique 
tumor-specific antigens, as well as shared tumor antigens 
common to many types of cancer,” said Dr. Hu. 
Their discovery may have significant implications for 
cancer vaccine development, with the potential to invoke 
immunity against many types of cancer.
CANCER VACCINES 2.0
Research by Dr. Hu’s lab has contributed to a better 
understanding of the functions of nanoparticles and 
ubiquitinated proteins in antigen cross-presentation, and 
how they may be used to boost cancer immunity – a 
partial representation of the advancements made by his 
lab in illuminating the role of autophagy in cancer 
immunotherapy. 
“When designing cancer vaccines, scientists now 
realize we need to identify patients’ unique tumor-
specific antigens, as well as shared antigens, to optimize 
immune responses,” said Dr. Hu. “Our research 
demonstrates there is potential to develop a shared 
immune response by vaccination, and these discoveries 
have application for the next generation of cancer 
vaccines.”
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Our research demonstrates there is 
potential to develop a shared immune 
response by vaccination, and these 
discoveries have application for the 
next generation of cancer vaccines.
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Cancer Immunotherapy 
Laboratory
William L. Redmond, Ph.D., is investigating 
how limiting or reversing tumor-induced 
immune suppression, together with the 
administration of immune-modulating 
antibodies, may improve survival for patients 
with cancer.
Recent developments in cancer immunotherapy have 
displayed its potential to improve overall patient survival, 
particularly when therapies are combined and optimized 
for maximum clinical benefit. Indeed, for certain cancers, 
such as melanoma, lung cancer, advanced head and neck 
cancer and some blood cancers, immunotherapy is now 
regarded as a standard of care alongside chemotherapy, 
radiation and surgery. 
Yet, as reported in the European Journal of Cancer, 
Dr. Redmond and colleagues describe several challenges 
– from treatment dose, schedule and duration to the 
need for clinical biomarkers – facing the field today. 
“Even when immunotherapy agents are combined, 
we find that some patients with cancer do not 
experience clinical benefit, due in part to the immune-
suppressing effects of the tumor microenvironment,” 
said Dr. Redmond. “The next generation of cancer 
immunotherapy will need to incorporate agents that 
block or reverse immune suppression to improve overall 
patient survival.” 
Dr. Redmond’s lab is examining whether inhibition 
of galectin-3, a protein known to promote cancer growth 
and immune suppression, enhances the therapeutic 
effects of immunotherapy. 
William L. Redmond, Ph.D., associate member, Cancer Immunotherapy Laboratory, 
and director, Immune Monitoring Laboratory
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GALECTIN-3 INHIBITION
Found in a variety of cancer cells, galectin-3 is associated 
with poor prognosis and is present at high production 
levels in patients with metastatic cancer. Galectin-3 is 
also known to attract myeloid-derived suppressor cells, 
or MDSCs, a type of immune cell with regulatory and 
suppressive functions. Tumors bearing high infiltration of 
MDSCs have shown resistance to immunotherapy. 
Dr. Redmond’s team speculated that GR-MD-02, 
a galectin-3 inhibitor, and anti-OX40, an immune-
stimulating antibody, would synergize to mediate cancer 
regression. Using a preclinical model, they studied 
the combination in cancers of the prostate, breast and 
connective tissues. Compared to anti-OX40 therapy 
alone, they observed the therapeutic combination was 
more effective in reducing the frequency of MDSCs 
within the tumor microenvironment, thus limiting 
immune suppression and enhancing overall survival. 
In other preclinical studies, they evaluated GR-
MD-02 with an anti-PD-1 antibody, a checkpoint 
immunotherapy approved for several cancers, and found 
additional evidence of clinical benefit. “Our studies 
revealed that galectin-3 inhibition in conjunction with 
immune-modulating antibodies enhanced tumor-specific 
immunity and improved survival in preclinical models,” 
said Dr. Redmond. “Our next step was to test these novel 
combinations in patients.”
FIRST-IN-HUMAN CLINICAL TRIAL
In collaboration with Brendan D. Curti, M.D., member 
and director, Cytokine and Adoptive Immunotherapy 
Program, Dr. Redmond opened a first-in-human, phase I 
clinical trial testing the safety and immunological effects 
of GR-MD-02 in combination with pembrolizumab, 
an anti-PD-1 antibody, in patients with melanoma, 
lung cancer and head and neck cancer. The investigator-
initiated study is a collaboration of Providence Health & 
Services and the pharmaceutical sponsor with support 
from the National Cancer Institute.  
Of the nine patients enrolled to the trial, five 
experienced regression of their cancers in response 
to therapy. “The clinical responses seen in this study 
are encouraging, and we are making progress on 
identifying immunological biomarkers that may predict 
clinical responses,” said Dr. Redmond. “As our studies 
demonstrate, patients who respond to the combination 
of GR-MD-02 and pembrolizumab may have reduced 
MDSCs following treatment – a potential biomarker 
which may guide the development of future studies.” 
Preliminary results from the clinical trial, along with 
data from the corresponding preclinical studies, were 
presented by Dr. Redmond’s laboratory at the 2017 
annual meeting of the Society for Immunotherapy of 
Cancer, which awarded the team a Young Investigator 
Travel Award based on the quality of their research and 
potential to advance the field.
Drs. Redmond and Curti plan to open another phase 
I clinical trial in the future, testing GR-MD-02 and an 
anti-OX40 antibody in patients with metastatic cancer, 
to offer more patients hope for improved survival.
The next generation of cancer 
immunotherapy will need to 
incorporate agents that block or 
reverse immune suppression to 
improve overall patient survival.
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Integrated Therapies 
Laboratory
As principal investigators of two R01 Research 
Project grants from the National Cancer 
Institute, Michael J. Gough, Ph.D., and Marka 
R. Crittenden, M.D., Ph.D., are examining the 
combination of highly targeted radiation 
therapy with novel immunotherapies for 
cancer. Together, they lead the Integrated 
Therapies Laboratory.
The role of radiation therapy as an immunotherapeutic 
agent is a subject of ongoing research. Yet preclinical 
studies indicate high-dose radiation therapy is effective 
in mediating cancer regression when paired with 
immunotherapy. 
In the prevailing theory, radiation therapy eradicates 
cancer cells, which are processed by the immune 
system, prompting an influx of cancer-killing CD8 T 
cells to the tumor site. Checkpoint immunotherapies 
counteract the immune-suppressing forces of the tumor 
microenvironment, which enables the elimination of 
residual cancer cells that survive radiation. Drs. Gough 
and Crittenden tested this concept, and their findings 
may guide the combination of these therapies for treating 
patients with cancer.
RADIATION VS LISTERIA VACCINATION
The bacteria Listeria monocytogenes is in development as 
a potential immune-based cancer therapy. One strategy 
shown to generate anti-cancer immune responses uses a 
modified form of Listeria as a cancer vaccine.
Marka R. Crittenden, M.D., Ph.D., associate member, Integrated Therapies Laboratory, 
and director, Translational Radiation Research, and Michael J. Gough, Ph.D., associate 
member, Integrated Therapies Laboratory
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In a preclinical pancreatic cancer model, Drs. Gough 
and Crittenden compared high-dose radiation therapy 
and a Listeria vaccine platform. They analyzed the ability 
of both agents to generate anti-cancer immune responses 
when combined with an anti-PD-1 antibody, a type 
of checkpoint immunotherapy. They observed Listeria 
vaccination prompted a greater increase in the number 
of tumor-reactive T cells than radiation. However, the 
vaccine failed to provide an advantage over radiation in 
controlling tumor growth. 
“In our experiments, generating large numbers of 
tumor-reactive T cells by Listeria vaccination did not 
substitute for the efficacy of radiation and an anti-PD-1 
antibody,” said Dr. Gough. “This leads us to question 
whether the main driver of radiotherapeutic efficacy is 
to increase the number of CD8 T cells, and provides 
guidance for future investigations.” 
These findings, which confirm the benefits of 
radiation therapy as a partner for checkpoint 
immunotherapy, were presented by their lab at the  
2017 annual meeting of the Society for Immunotherapy 
of Cancer. 
INNATE AND ADAPTIVE IMMUNITY
In other experiments, Drs. Gough and Crittenden are 
using Listeria vaccination to study innate and adaptive 
immune responses to cancer. Whereas the innate 
immune system initiates immune responses, an adaptive 
immune response can provide long-term immunity.
In a preclinical model, their lab evaluated an approach 
to amplify the inflammatory immune response to Listeria 
by modifying expression of suppressor of cytokine 
signaling 1, or SOCS1, a protein known to suppress 
inflammation. They reasoned loss of the SOCS1 protein 
in dendritic cells, a cell that links innate and adaptive 
immune responses, would boost immune activation and 
increase T-cell responses.
By testing the Listeria vaccine in dendritic cells 
engineered to lack SOCS1, they compared results from 
in vitro experiments with those performed in living 
organisms, known as in vivo experiments. Contrary to 
their expectations, they observed a decrease in CD8 T-cell 
responses. As reported in the Journal of Immunology, 
dendritic cells lacking SOCS1 expression were functional, 
but failed to generate an efficient adaptive immune 
response. When the innate immune response increased, 
the adaptive immune response decreased.
“We demonstrated for the first time that cell-specific 
loss of SOCS1 in dendritic cells in vivo redirects the 
immune response following Listeria vaccination away 
from an adaptive response and toward an innate 
response,” said Dr. Crittenden. “Strategies that aim 
to generate cancer immunity by means of CD8 T-cell 
meditation may need to avoid over-activation of cross-
presenting dendritic cells to optimize the adaptive 
immune response.”
Their discovery, albeit surprising, is yielding new 
directions of research. Drs. Gough and Crittenden have 
applied these insights to other areas of investigation in 
their laboratory with the hope of improving therapies for 
patients with cancer.
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We demonstrated for the first time that 
cell-specific loss of SOCS1 in dendritic 
cells in vivo redirects the immune 
response following Listeria vaccination 
away from an adaptive response and 
toward an innate response.
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Molecular and Tumor 
Immunology Laboratory
An expert in tumor immunology and 
immune profiling, Bernard A. Fox, Ph.D., is 
investigating immunotherapy mechanisms 
of action and methods of tumor immune 
escape. By developing novel biomarkers, his 
lab is advancing technology which may help 
clinicians predict patient responses to therapy.
The development of checkpoint immunotherapies 
improved clinical outcomes for patients with melanoma, 
lung cancer and other malignancies. Yet for patients with 
breast cancer, the second-leading cancer diagnosis among 
women in the United States, these therapies provided 
limited benefit.
Seeking to optimize clinical benefit for these patients, 
Dr. Fox and his team examined whether the timing and 
sequence of immunotherapy combinations affect clinical 
outcomes. Their findings reveal significant insights, 
which may improve the administration of cancer care 
and immunotherapy clinical trials for patients with breast 
cancer and other malignancies.
IMMUNOTHERAPY SEQUENCING
In a preclinical breast cancer model, his lab tested the 
combination of two immune-modulating antibodies – 
anti-PD-1 and anti-OX40 – compared to both therapies 
given alone, which yielded unexpected findings. “We 
were really surprised to see the simultaneous combination 
of anti-OX40 and anti-PD-1 was less effective than either 
therapy given alone,” said Dr. Fox. Equally surprising, 
when anti-OX40 was given prior to anti-PD-1, but not 
Bernard A. Fox, Ph.D., member and Harder Family Endowed Chair for Cancer Research, 
Molecular and Tumor Immunology Laboratory
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in the reverse order, the sequential combination showed 
the greatest clinical benefit of all their study models. 
“The timing and sequence of the two agents had 
a profound impact on their biological effects,” said 
Dr. Fox. Anti-OX40 administered prior to anti-
PD-1 provided an apparent 30 percent cure rate in a 
previously incurable model. These results, published 
in Clinical Cancer Research, drew the attention of the 
National Cancer Institute and the American Association 
for Cancer Research. In articles featuring Dr. Fox’s 
study, both organizations noted the need for a better 
understanding of the biological mechanisms of action 
when immunotherapies are combined in clinical trials.
“Our research demonstrates the need for 
well-controlled clinical trials of immunotherapy 
combinations. I think that is how we are going to make 
greater progress against cancer,” said Dr. Fox. 
IMMUNE PROFILING
To evade detection and elimination by the immune 
system, tumors employ multiple mechanisms of immune 
escape. By analyzing patients’ immune profiles and their 
tumors, such as the type and frequency of tumor-killing 
T cells that infiltrate tumors and how tumors escape 
detection, clinicians may gain valuable insights to guide 
their treatment strategies.
As an investigator of the global Immunoscore study, 
an independent prognostic tool shown to predict 
recurrence and survival in patients with colorectal cancer, 
Dr. Fox and his lab are at the forefront of developing 
prognostic biomarkers for cancer. In collaboration with 
his Immunoscore co-investigator Carlo B. Bifulco, M.D., 
member and director, Translational Molecular Pathology, 
along with R. Bryan Bell, M.D., D.D.S., FACS, and 
Rom S. Leidner, M.D., assistant members and  
co-directors, Providence Head and Neck Cancer 
Program, Dr. Fox assessed the immune profiles of 
119 patients with HPV-negative oral squamous cell 
carcinoma, a type of head and neck cancer. 
Using multispectral imaging and objective assessment 
tools, they performed the first comprehensive immune 
profiling study of patients with this disease. Evaluation 
of six biomarkers revealed a positive correlation between 
patient survival and increased tumor-infiltrating  
T cells, with a concurrent absence of immune 
suppression mechanisms. 
“By examining tissue biomarkers in an individual 
patient’s tumor, doctors may be able to make better 
predictions of which immunotherapies will generate the 
most effective anti-cancer immune response,” said Dr. 
Fox. “Our study suggests that the evaluation of multiple 
parameters is necessary to identify patients in need of 
more aggressive treatment strategies.” 
Dr. Fox presented results of the study at a joint 
workshop of the Food and Drug Administration and 
the American Association for Cancer Research. His lab 
is collaborating with colleagues around the world to 
improve technologies and assessment techniques needed 
for the development of validated biomarkers to aid 
clinicians in real-time decision-making. 
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By examining tissue biomarkers 
in an individual patient’s tumor, 
doctors may be able to make 
better predictions of which 
immunotherapies will generate 
the most effective anti-cancer 
immune response.
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Tumor Microenvironment 
Laboratory
As a radiation oncologist and immunologist, 
Kristina H. Young, M.D., Ph.D., is studying how 
immunotherapy can remodel patients’ tumor 
environments to increase the effectiveness of 
conventional cancer therapies. 
For patients with colorectal cancer, the most common 
cancer among men and women in the United States after 
breast, prostate and lung cancers, conventional cancer 
therapies – chemotherapy, radiation and surgery – have 
been the mainstay of treatment for decades. Nevertheless, 
colorectal cancer remains the fourth-leading cause of 
cancer death in this population, prompting a surge 
of investigation into combining immunotherapy and 
conventional therapy to improve survival. Dr. Young leads 
an innovative clinical trial testing a novel immunotherapy 
in combination with chemoradiation, offering hope to 
patients with this lethal disease.
TUMOR IMMUNE INFILTRATION
Studies show a correlation between patient survival and 
infiltration of their tumors by cancer-killing CD8 T cells, 
regulatory T cells, known as Tregs, and macrophages, 
another immune cell with regulatory functions. Tumors 
exhibiting little infiltration of CD8 T cells, increased 
macrophage infiltration and a high ratio of Tregs to  
CD8 T cells are associated with a poor tumor immune 
profile, or low immune score. In patients with colorectal 
cancer, low immune scores are linked to decreased overall 
survival, and high scores correlate with improved survival.Kristina H. Young, M.D., Ph.D., assistant member,  
Tumor Microenvironment Laboratory
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Seeking to improve prognosis for these patients, 
Dr. Young studied whether modifying patients’ tumor 
immune environments can improve their responses to 
therapy. She tested whether inhibiting transforming 
growth factor beta, or TGF-ß – a protein with important 
immune signaling functions, would increase the 
effectiveness of radiation therapy. 
TGF-ß INHIBITION
Through its signaling pathway, TGF-ß aids in cellular 
proliferation and differentiation, and the activation of 
immune cells. In cancer cells, however, mutations may 
alter the signaling pathway, leading to cancer growth and 
a tumor environment with poor immune infiltration. 
Blocking the TGF-ß pathway can disrupt these cancer-
promoting forces. 
“Our experiments demonstrate that pretreatment 
TGF-ß blockade improved the tumor immune 
environment in preclinical models, and significantly 
improved the effectiveness of subsequent radiation 
therapy,” said Dr. Young. “We demonstrated that this 
effect was entirely dependent on CD8 T cells, and 
generated long-term, tumor-specific protection.”
ONE-OF-A-KIND CLINICAL TRIAL 
Armed with promising preclinical data, Dr. Young 
wasted no time in offering this novel combination to 
patients with colorectal cancer. By participation in her 
phase II, investigator-initiated study – the first of its kind 
worldwide, patients diagnosed with stage II and higher 
rectal cancer who are slated for conventional therapy  
may opt to receive immunotherapy as part of their 
treatment regimens. 
Galunisertib, a small molecule inhibitor of TGF-ß, 
is administered to patients in the form of daily pills for 
two weeks prior to radiation and chemotherapy, and 
continued throughout their treatments. 
Of 50 patients expected to participate, the first three 
patients experienced a dramatic response: one patient’s 
tumor disappeared completely, and the others had more 
than a 75 percent decrease in tumor size, with equally 
impressive responses in their lymph nodes. 
The study also seeks to evaluate patients’ immune 
scores as potential biomarkers to predict therapeutic 
response. By monitoring patients’ immune responses 
throughout treatment, and correlating changes in 
their tumor immune infiltrate to imaging analysis and 
treatment response, Dr. Young hopes to aid in the 
development of a prognostic tool to guide treatment 
decisions. In patients who respond to treatment, she 
expects to see remodeling of their tumor environments 
toward a more favorable immune score with increased 
CD8 T cells, decreased macrophages and a low 
Treg:CD8 T-cell ratio.
“Our studies demonstrate there are significant 
opportunities to manipulate the immune environment 
of tumors for therapeutic gain. These initial responses are 
very exciting and make us hopeful that this therapy will 
improve outcomes for patients with this deadly disease,” 
said Dr. Young. 
Preliminary results were presented by her lab at the 
2017 annual meetings of the American Society for 
Radiation Oncology and the Society for Immunotherapy 
of Cancer, among other conferences.
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Our studies demonstrate there are 
significant opportunities to manipulate 
the immune environment of tumors 
for therapeutic gain.
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Breast Cancer
Together, Alison K. Conlin, M.D., MPH, and 
David B. Page, M.D., oversee a vast portfolio 
of clinical trials and therapies for patients 
with breast cancer. From early-stage disease 
to metastatic and triple-negative breast 
cancer, they seek to improve quality of life and 
survival for patients with this pervasive cancer.
In addition to being the most common cancer among 
women in the United States after skin cancer, breast 
cancer is also one of the deadliest, second only to deaths 
from lung cancer. By conducting novel studies, Drs. 
Conlin and Page hope to improve breast cancer care so 
that more patients will benefit.
PREOPERATIVE IRX-2 
Dr. Page devised a phase I clinical trial testing an 
experimental immunotherapy in women and men 
diagnosed with stage I-III breast cancer. The study 
includes patients with triple-negative breast cancer, a 
type of breast cancer in which three common receptors – 
estrogen, progesterone and HER2 – are absent, making 
it one of the most difficult forms to treat. He examined 
whether IRX-2, an immune-boosting cytokine therapy 
shown to shrink tumors in other cancers, improves 
clinical responses when administered prior to surgery.
For 10 consecutive days, patients received local 
injections of IRX-2 as preoperative therapy. A mild 
chemotherapy was also administered prior to surgery to 
deplete T regulatory cells, a type of immune-suppressing 
cell. Tumor and blood samples were assessed for the 
David B. Page, M.D., assistant member, Breast Cancer Immunotherapy, and
Alison K. Conlin, M.D., MPH, associate member and medical director,  
Providence Breast Cancer Medical Program and High-Risk Breast Clinic
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presence of immune activation markers and tumor-
infiltrating lymphocytes, or TILs – signs that IRX-2 
treatment boosted patients’ immune responses. TILs are 
associated with improved survival in patients with early-
stage breast cancer.
“We found that IRX-2 was well-tolerated with 
preliminary evidence of increased TIL recruitment, 
peripheral lymphocyte activation and T-regulatory 
depletion,” said Dr. Page. He presented early results of 
the trial, which is ongoing, at the 2017 annual meeting 
of the Society for Immunotherapy of Cancer.
HER2CLIMB
Roughly 20 percent of breast cancers test positive for 
HER2, a protein known to promote cancer growth. 
HER2-positive tumors can spread more quickly and are 
less sensitive to hormone therapy than other types of 
breast cancer.
Therapies that target the HER2 protein can be 
effective, particularly in early-stage disease. For patients 
with metastatic cancer, however, five-year survival 
outcomes are a dismal 22 percent. “When treating 
metastatic breast cancer, often our goal is to halt its 
growth and keep it from traveling to new places in the 
body,” said Dr. Conlin. Brain metastases are common in 
patients with advanced disease.
An investigator on the global HER2CLIMB 
study, Dr. Conlin is evaluating whether tucatinib, an 
experimental inhibitor of HER2, might improve survival 
in patients with HER2-positive breast cancer. The phase 
I/II study tests tucatinib in combination with targeted 
therapies in patients with locally advanced or metastatic 
HER2-positive breast cancer. 
The study is ongoing, and preliminary results were 
presented at the European Society for Medical Oncology 
2017 Congress and the 2017 San Antonio Breast Cancer 
Symposium. “Our findings demonstrate 20 percent of 
patients treated with tucatinib combinations for advanced 
breast cancer were free of progressing disease at 16 months 
or more,” said Dr. Conlin. “These women, many whose 
cancers had spread to the brain, benefited from extended 
disease survival for a significant period of time.”
CANCER-RELATED FATIGUE
Designated a high-priority area of research by the 
National Cancer Institute, cancer-related fatigue, or  
CRF, is a common complaint among breast cancer 
patients, affecting quality of life and treatment adherence. 
Dr. Conlin engaged in a nationwide, longitudinal study 
comparing CRF in women with breast cancer to women 
without cancer. “We found that breast cancer survivors 
experience significantly more CRF prior to and after 
chemotherapy compared to healthy patients,” said  
Dr. Conlin. 
Study results drew the attention of the American 
Society of Clinical Oncology, which published the 
findings and an accompanying editorial in its Journal 
of Clinical Oncology. The society, whose annual report 
noted CRF management among the most important 
patient care advances of the year, also selected the study 
for presentation at its 2017 annual meeting. 
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These women, many whose cancers 
had spread to the brain, benefited 
from extended disease survival for a 
significant period of time.
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Cytokine and Adoptive 
Immunotherapy
An expert in cytokine and adoptive 
immunotherapy, Brendan D. Curti, M.D., is 
engaged in numerous investigator-initiated 
and industry-sponsored clinical trials to 
improve survival of patients with cancer.
Cytokines are proteins with cell-signaling functions 
important in regulating immune responses, and are 
instrumental in rejecting cancers. Interleukin-2, known 
as IL-2, is a type of immune-boosting cytokine proven 
to be effective when administered in high doses to 
patients with melanoma and renal cell carcinoma, a type 
of kidney cancer. Dr. Curti oversees one of the busiest 
programs in the country for high-dose IL-2, and the 
largest program on the West Coast.
PROCLAIM STUDY
Like other immunotherapies, IL-2 can induce 
unexpected complications, such as immune-related 
adverse events – or irAEs, ranging from reversible 
symptoms to potentially life-threatening side effects. 
Common irAEs include thyroid dysfunction and vitiligo, 
a condition causing the loss of skin color. While some 
studies suggest a positive association between irAEs and 
patient survival, consensus among medical professionals 
is lacking. 
Seeking to provide contemporary assessment of the 
relationship between clinical benefit and irAEs from 
IL-2, Dr. Curti is the lead author of a nationwide, 
multicenter observational study, known as PROCLAIM, Brendan D. Curti, M.D., member and director, Cytokine and Adoptive Immunotherapy 
Program, Genitourinary Oncology Research and Providence Melanoma Program
22 LABORATORY RESEARCH: Antitumor T-cell Response Laboratory 23
to evaluate the treatment patterns and clinical responses 
of high-dose IL-2 in patients with metastatic renal cell 
carcinoma and metastatic melanoma. Of the 1,535 
patients enrolled to the study from 2008 to 2016, 130 
patients experienced irAEs. As reported in the Journal for 
ImmunoTherapy of Cancer, the development of irAEs 
related to IL-2 is associated with significantly improved 
overall survival compared to patients with no irAEs. 
 “Our study supports the association of immune 
activation from immunotherapy with better patient 
outcome,” said Dr. Curti. “Although it would be ideal 
for patients to have immunotherapy with no side effects, 
this work supports that clinical benefit is linked with side 
effects related to the immune activity of IL-2.” 
PIVOT-02 STUDY
Dr. Curti is investigating another cytokine showing 
promise when given with checkpoint immunotherapy in 
patients with advanced solid cancers. As a lead investigator 
of the phase I/II multicenter clinical trial known as 
PIVOT-02, he is studying NKTR-214, a chemically 
modified form of IL-2, given in combination with 
nivolumab, an anti-PD-1 checkpoint immunotherapy 
approved for treating a variety of cancers. 
Preclinical studies indicate NKTR-214 boosts the 
proliferation of cancer-killing CD8 T cells within 
the tumor microenvironment without increasing the 
activity of immune-suppressing T regulatory cells. 
These properties are due to its pegylation, a chemical 
modification which alters the receptor binding of 
IL-2. NKTR-214 also enhances expression of PD-
1, an immune checkpoint protein responsible for 
regulating immune responses. Through inhibiting 
PD-1, nivolumab increases the life span and activity of 
T cells, which can facilitate the destruction of cancer. 
Investigators hypothesized that the complementary 
mechanisms of action of these two immunotherapies 
would result in greater overall survival than seen in either 
therapy alone. 
When given as first- or second-line therapy to 38 
patients with multiple tumor types, responses were 
observed in 46 percent of patients with renal cell 
carcinoma, 64 percent with melanoma, and 75 percent 
with non-small cell lung cancer. Patients with bladder 
cancer and triple-negative breast cancer are also eligible 
to enroll.
“By increasing the proliferation of CD8 T cells in 
the tumor and increasing PD-1 expression, NKTR-
214 demonstrated a potentially synergistic mechanism 
with anti-PD-1 therapy, confirming observations from 
the preclinical studies,” said Dr. Curti.  “These data 
demonstrate that NKTR-214 and nivolumab are well-
tolerated in the outpatient setting with encouraging 
response rates, and warrant further investigation.”
Investigators aim to enroll 350 patients across 13 
cohorts in the phase II study, and a second study arm 
was added to test NKTR-214 in combination with 
nivolumab and ipilimumab, another checkpoint 
immunotherapy approved for several cancers. The study 
was selected for oral abstract presentation at the 2017 
annual meeting of the Society for Immunotherapy of 
Cancer, and presented at other major conferences in the 
United States and Europe.
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Our study supports the association of 
immune activation from immunotherapy 
with better patient outcome.
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Gastrointestinal Cancer
From novel surgical techniques to innovative 
immunotherapy studies, Todd S. Crocenzi, 
M.D., and Pippa H. Newell, M.D., seek 
to improve outcomes for patients with 
gastrointestinal cancers.
MISMATCH-REPAIR BREAKTHROUGH
In collaboration with researchers at Johns Hopkins 
University, Dr. Crocenzi demonstrated that patients with 
advanced colorectal cancer were responsive to anti-PD-1 
checkpoint immunotherapy when their tumors were 
defective in repairing mismatched DNA. 
This deficiency, known as mismatch repair – or 
MMR, occurs when cells lack the ability to correct errors 
in DNA replication. When left uncorrected, these errors 
– known as mutations – accumulate in vast quantities, 
acting as targets of anti-tumor immune responses.  
A phase II study by Dr. Crocenzi and colleagues  
revealed that pembrolizumab, an anti-PD-1 checkpoint  
inhibitor approved for numerous cancers, was effective  
in mediating cancer regression in patients with MMR-
deficient colorectal cancers bearing high numbers  
of mutations.
While only a minority of patients with colorectal 
cancer have MMR-deficient tumors, the investigators 
hypothesized that other patients who shared the 
deficiency would also benefit from anti-PD-1 therapy 
regardless of where their tumors originated. They tested 
this premise by expanding their study to include 12 types 
of advanced MMR-deficient cancer, such as pancreas, 
prostate, uterine and bone cancers.
Pippa H. Newell, M.D., assistant member and medical director, Providence 
Liver Cancer Clinic, and Todd S. Crocenzi, M.D., associate member and director, 
Gastrointestinal Oncology Research
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As reported in the journal Science, their premise was 
correct: 66 of 86 patients enrolled to the trial saw their 
tumors shrink or stabilize. In 18 of those responders, 
their tumors vanished completely. “Based on these 
responses, our estimates of overall survival at one and two 
years were 76 percent and 64 percent, which is markedly 
higher than expected due to the advanced state of disease 
in these patients,” said Dr. Crocenzi. 
The results drew national headlines, including an 
article in The New York Times, and spurred the Food  
and Drug Administration to accelerate approval of 
pembrolizumab for MMR-deficient cancers, marking  
the first instance of a cancer drug approval based on a 
shared genetic profile rather than cancer type or site  
of origination. 
Testing for MMR deficiency is widely available, and 
the investigators estimate up to 60,000 cancer patients 
annually could benefit. “These results tie immunity, 
cancer genetics and therapeutics together in a manner 
that will likely establish a new standard of care,” said  
Dr. Crocenzi.
HCC APPROVAL
For patients with advanced hepatocellular carcinoma, or 
HCC – the most common type of primary liver cancer, 
outcomes remain poor, limited by a lack of treatment 
options. Dr. Crocenzi and other collaborators conducted 
a phase I/II study of nivolumab, another anti-PD-1 
checkpoint inhibitor, in patients with HCC. 
In an article for The Lancet, they reported a favorable 
safety profile and early evidence of clinical activity. Dr. 
Crocenzi presented preliminary results of the study at 
the 2017 annual meeting of the American Society of 
Clinical Oncology, where he noted durable responses 
were observed with long-term survival. Soon after, the 
FDA granted nivolumab accelerated approval for patients 
with advanced HCC whose cancers progressed following 
systemic therapy – the first immunotherapy approved for 
this population. 
FRS VALIDATION
As a liver and pancreas surgeon, Dr. Newell is engaged 
in studies to improve surgical techniques and patient 
outcomes. With colleagues at Providence Cancer 
Institute, she evaluated a risk assessment tool to predict 
the postsurgical onset of pancreatic fistula following 
pancreaticoduodenectomy – the most common 
operation to treat pancreatic cancer – also known 
as a Whipple procedure. Consisting of abnormal 
communication between the pancreas and surrounding 
organs, pancreatic fistula is the most common 
complication arising from this procedure, and can be 
life-threatening.
They conducted a prospective assessment of four 
centers in the United States and Canada, evaluating 
the use of Fistula Risk Score, or FRS, in a total of 
444 patients undergoing the operation. As reported 
in the journal HPB, their findings strengthened the 
clinical validity of FRS. “We can now predict the risk 
of pancreatic fistula intraoperatively with satisfactory 
accuracy,” said Dr. Newell.
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These results tie immunity, cancer 
genetics and therapeutics together in 
a manner that will likely establish a 
new standard of care.
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Genomics
An expert in translational molecular pathology, 
Carlo B. Bifulco, M.D., is engaged in numerous 
studies to characterize the tumor immune 
environment through genome sequencing and 
advanced immunohistochemistry and image 
analysis techniques. 
PERSONALIZED MEDICINE
In the past decade, advances in genome sequencing have 
enabled real-time, high-throughput DNA sequencing 
– also known as next-generation sequencing, or 
NGS. As the costs of NGS continue to fall, access by 
physicians and patients to this powerful diagnostic and 
predictive tool has increased, and ushered in a new era of 
personalized medicine. 
As medical director of Molecular Genomics, Dr. 
Bifulco leads the Oregon hub of Providence Personalized 
Medicine Program, the systemwide NGS program of 
Providence St. Joseph Health. The program is available to 
test samples from patients with solid tumors and blood 
cancers who are receiving standard-of-care therapies 
or participating in clinical trials. Tests include targeted 
panels, whole exome and RNA sequencing.
Dr. Bifulco is aided by computational and systems 
biologist Brady Bernard, Ph.D., genomic scientist 
Brian Piening, Ph.D., and a team of bioinformaticists. 
They use state-of-the-art equipment, custom-built 
bioinformatics pipelines and sophisticated computational 
models to identify genetic mutations in patients’ tumors. 
Some mutations may be targeted therapeutically, lending 
valuable insight to clinicians for the development of 
individualized treatment plans based on patients’ unique 
genetic profiles.
Carlo B. Bifulco, M.D., member and director, Translational Molecular Pathology, 
and medical director, Molecular Genomics
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PRECISION IMMUNOTHERAPY
Through the integration of genomics and immunotherapy, 
it is now possible to identify neoantigens, proteins encoded 
by tumor-specific mutated genes, to serve as targets of 
immunotherapy. 
With extensive experience in the development of 
NGS assays for immune profiling, Dr. Bifulco’s team 
is at the forefront of harnessing the power of genomics 
for precision immunotherapy. “We developed a 
comprehensive solid tumor NGS panel with the dual 
purpose of detecting clinically relevant, targetable 
regions of the genome and identifying neoantigens for 
immunotherapy applications,” said Dr. Bifulco. 
They were invited to give presentations highlighting 
their expertise in NGS for immunotherapy at the 
2017 annual meeting of the Association for Molecular 
Pathology.
TRI-SEQ NGS STUDY
In collaboration with Rom S. Leidner, M.D., assistant 
member and co-director, Providence Head and Neck 
Cancer Program, and other investigators, Dr. Bifulco leads 
a clinical trial to study the effects of patients’ genomes 
on their responses to immunotherapy. The study, known 
as Tri-Seq NGS, aims to characterize neoantigens by 
harnessing three complementary levels of genetic data: 
tandem DNA and RNA sequencing from tumor samples, 
and DNA sequencing from normal tissue. Dr. Bifulco’s 
team uses novel computational approaches to mine for 
molecular differences between tumor and normal cells 
that can be targeted by immunotherapies.
The study supports essential functions of the 
Antitumor T-cell Response Laboratory led by Assistant 
Member Eric Tran, Ph.D. Dr. Tran is an expert in 
adoptive cell therapy, a promising approach to curing 
cancer by amplifying patients’ tumor-killing T cells 
in the lab and giving them back to patients in greater 
quantities. Dr. Tran will partner with Dr. Bifulco and 
other clinicians to create highly personalized, genome-
guided immunotherapies.
Tri-Seq NGS is open to patients with head, neck, 
pancreas and other types of cancer, and Dr. Tran plans 
to begin clinical trials as early as 2019. “We hope the 
knowledge acquired through genome sequencing will 
lead us to cures for cancer,” said Dr. Bifulco.
IMMUNOSCORE
Together with Bernard A. Fox, Ph.D., member 
and Harder Family Chair, Molecular and Tumor 
Immunology Laboratory, Dr. Bifulco serves on a global 
study supported by the Society for Immunotherapy 
of Cancer to incorporate the immune contexture 
into cancer staging and classification. By analyzing 
the immune contextures of more than 3,000 cancer 
patients, investigators have developed a new scoring 
system, known as Immunoscore, to help predict patient 
outcomes to therapy. 
An article in the Journal of Translational Medicine 
co-written by Dr. Bifulco suggests Immunoscore may 
become a new component of cancer classification based 
on immune parameters. “This will represent the first 
standardized immune-based assay for classifying cancer 
in the era of immunotherapy,” said Dr. Bifulco.
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We hope the knowledge acquired 
through genome sequencing will lead 
us to cures for cancer.
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Head and Neck Cancer
As co-directors of Providence Head and Neck 
Cancer Program, Rom S. Leidner, M.D., and 
R. Bryan Bell, M.D., D.D.S., FACS, oversee one 
of the largest immunotherapy clinical trial 
portfolios for head and neck cancer on the 
West Coast. 
Head and neck cancer accounts for nearly 50,000 new 
cancer diagnoses in the United States annually, and is  
the sixth most common cancer worldwide. While five-
year survival rates for early-stage disease are 83 percent, 
only 38 percent of patients with advanced cancers  
survive beyond five years. Drs. Bell and Leidner lead 
innovative immunotherapy studies to improve survival 
for these patients.
ANTI-OX40 PHASE I STUDY
Head and neck squamous cell carcinomas, or HNSCC, 
are known to produce suppressive factors which can 
impair anti-cancer immune responses. Drs. Bell and 
Leidner hypothesized that anti-OX40, an experimental 
immune-stimulating antibody developed at the Earle A. 
Chiles Research Institute, may enhance the activation of 
tumor-killing T cells when administered before surgery. 
They are testing this concept in an investigator-initiated, 
phase I clinical trial to evaluate the effectiveness and 
safety of anti-OX40 given before conventional surgical 
resection in patients with locally advanced HNSCC.
Beginning two weeks before surgery, patients received 
intravenous infusion of anti-OX40. Tumor and blood 
samples were obtained prior to anti-OX40 treatment and 
at the time of surgery to assess the effects of anti-OX40 
Rom S. Leidner, M.D., assistant member and co-director, Providence Head and 
Neck Cancer Program, and R. Bryan Bell, M.D., D.D.S., FACS, assistant member 
and medical director, Providence Head and Neck Cancer Program and Clinic
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on tumor-infiltrating immune cell populations and other 
immunological functions. The study is the most in-depth 
analysis of immune response conducted in a surgical trial, 
representing a pioneering collaboration with their clinical 
and scientific colleagues.
Dr. Bell presented preliminary results at the 2017 
International Conference on Oral and Maxillofacial  
Surgery. “We found that preoperative anti-OX40 is 
feasible and safe in patients with HNSCC, and results  
in the activation and proliferation of T-cell populations 
in both the tumor microenvironment and in circulation,” 
said Dr. Bell. Results from the ongoing study were 
also presented at the 2017 Head and Neck Cancer 
Conference, a joint meeting of the American Association 
for Cancer Research and the American Head and  
Neck Society. 
ADOPTIVE CELL THERAPY
Dr. Leidner is the first investigator in Oregon to 
offer patients with HNSCC adoptive cell therapy, or 
ACT. Celebrated as the Advance of the Year by the 
American Society of Clinical Oncology, ACT is a highly 
personalized immunotherapy in which patients’ tumor-
killing T cells are extracted, reinforced in a lab and 
reinfused in greater quantities.
Studies show the clinical benefit of ACT in cancers 
that bear many genetic mutations, or are virally 
associated. In collaboration with Brendan D. Curti, 
M.D., member and director, Cytokine and Adoptive 
Immunotherapy Program, Dr. Leidner is testing the 
safety and effectiveness of ACT in HNSCC, a cancer 
associated with human papillomavirus and a high 
number of mutations. 
In the phase II, multicenter study, patients receive 
reinfusion of their enhanced tumor-infiltrating 
lymphocytes, followed by interleukin-2, another 
immunotherapy shown to boost anti-cancer immune 
responses. The study is ongoing, and preliminary results 
were presented at the 2017 annual meeting of the Society 
for Immunotherapy of Cancer.
LIRILUMAB GLOBAL STUDY
In another phase I/II trial, Dr. Leidner is evaluating a 
combination of two immunotherapies for patients with 
advanced HNSCC and other solid tumors. 
Natural killer cells, or NK cells, play a critical 
role in immune surveillance and controlling tumor 
growth. Activation of NK cells is regulated in part 
by killer-cell immunoglobulin-like receptors, known 
as KIRs. Blocking KIR function may facilitate anti-
cancer immune responses, and synergize with other 
immunotherapies. To test this premise, Dr. Leidner 
is leading the global investigation of lirilumab, an 
experimental NK-cell inhibitor, in combination with 
nivolumab, an immune checkpoint inhibitor approved 
for several cancers. 
The study was presented at the 2017 International 
Congress on Targeted Anticancer Therapies, where 
preliminary results demonstrated clinical benefit. Of 
41 patients with HNSCC, 52 percent saw their tumors 
shrink or stabilize in response to therapy.  “We observed 
encouraging responses that were deep and durable in 
some patients,” said Dr. Leidner. “These findings warrant 
further study of this novel combination.”
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We observed encouraging 
responses that were deep and 
durable in some patients.
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Hematologic 
Malignancies
John E. Godwin, M.D., MS, is investigating 
novel immunotherapies for patients with 
hematologic malignancies, also known as 
blood cancers. 
Acute myeloid leukemia, or AML – a type of cancer 
arising from abnormal development of blood cells in 
the bone marrow, is a common type of leukemia in the 
United States; approximately 19,500 people are newly 
diagnosed each year. An acute disease that can progress 
rapidly if untreated, it is the most deadly leukemia 
among adults, with less than 28 percent of adult AML 
patients surviving beyond five years.
Also resulting from abnormal bone marrow cells, 
myelodysplastic syndromes, or MDS, are hematologic 
conditions marked by low numbers of blood cells. An 
estimated 14,000 new diagnoses of MDS occur annually, 
most of them in older adults. 
Considered a type of blood cancer, patients with 
MDS are assessed for their risk of developing AML. The 
World Health Organization classifies MDS by five risk 
groups ranging from very low risk to very high risk. For 
patients in the intermediate risk group, an estimated 33 
percent will develop AML within five years; in very high-
risk patients, the chance of developing AML within five 
years jumps to 84 percent. 
FIRST-IN-HUMAN STUDY
Dr. Godwin is among a global cohort of investigators 
testing a new immunotherapy in a phase I, first-in-John E. Godwin, M.D., MS, member and program leader, Hematologic Malignancies
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human study of adult patients with AML and MDS. 
Flotetuzumab, a bispecific antibody administered by 
intravenous infusion, is capable of binding to two 
distinct cell-surface molecules simultaneously. Through 
dual recognition of CD123, a molecule overexpressed 
in hematologic malignancies like AML and MDS, and 
CD3, another molecule known to stimulate the activity 
of cancer-killing T cells, flotetuzumab can redirect T cells 
toward their malignant targets.
While immunotherapy is effective in other cancers 
such as B-cell hematologic malignancies, AML has 
remained resistant to antibody-based therapies due to 
a lack of appropriate molecular targets. Yet for more 
than 90 percent of patients with AML, CD123 is 
highly expressed; in patients with MDS, the molecule 
is prevalent in more than 50 percent of patients. With 
evidence of anti-leukemic activity in preclinical studies 
of flotetuzumab, study investigators hoped the bispecific 
therapy would bring clinical benefit to patients with 
these formidable malignancies. 
The study, which is ongoing, is testing the safety and 
effectiveness of flotetuzumab in patients with refractory 
or relapsed AML, or intermediate to high-risk MDS. Of 
13 sites participating worldwide, five are in the United 
States, and Dr. Godwin is the only investigator on the 
West Coast enrolling patients to the study. 
Early results were presented at major conferences 
across the United States and Europe. At the 2017 annual 
meeting of the American Society of Hematology, Dr. 
Godwin was invited to present preliminary data in an 
oral abstract session. Of 57 patients participating in the 
trial, a minority were enrolled to a dose expansion cohort 
to determine the maximum tolerated dose. Among this 
group, 75 percent demonstrated anti-leukemic activity, 
and two patients experienced a complete response. 
“We have seen leukemia patients who are 
unresponsive to other therapies go into complete 
remission with this immunotherapy,” said Dr. Godwin. 
“These early study results are encouraging, and warrant 
further investigation.”
CHECKPOINT COMBINATION
In another abstract selected for presentation by the 
American Society of Hematology, Dr. Godwin, together 
with Bernard A. Fox, Ph.D., member and Harder 
Family Chair, Molecular and Tumor Immunology 
Laboratory, and Carlo B. Bifulco, M.D., member 
and director, Translational Molecular Pathology, and 
other investigators, reported translational results of 
the flotetuzumab study which support the rationale 
for its combination with anti-PD-1 checkpoint 
immunotherapy. 
Through advanced multispectral immuno-
histochemistry analysis, Dr. Godwin and colleagues 
assessed malignant and normal tissue samples from 
patients in the study. They observed synergistic anti-
cancer activity in AML treated with flotetuzumab and 
an anti-PD-1 checkpoint inhibitor. “These data suggest 
that combination with anti-PD-1 therapy may enhance 
the therapeutic effects of flotetuzumab in patients with 
refractory or relapsed AML,” said Dr. Godwin.
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We have seen leukemia patients 
who are unresponsive to other 
therapies go into complete 
remission with this immunotherapy.
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Melanoma
As experts in the clinical development of 
immunotherapy for melanoma, Brendan D. 
Curti, M.D., and Walter J. Urba, M.D., Ph.D., 
investigate combinations of experimental 
treatments and standard-of-care therapies  
to improve patient survival.
MITCI STUDY
Dr. Curti leads a phase I, investigator-initiated clinical 
trial of CVA21, an oncolytic and immunotherapeutic 
strain of coxsackievirus A21, in combination with 
standard-of-care ipilimumab, an anti-CTLA-4  
immune checkpoint inhibitor, in patients with  
advanced melanoma.
The study, known as Melanoma Intra-Tumoral 
Cavatak and Ipilimumab, or MITCI, is a collaboration 
between Providence Health & Services and the 
pharmaceutical sponsor. Patients receive injections 
of CVA21 in their melanoma lesions, followed by 
intravenous ipilimumab. A total of 60 patients are 
expected to participate at 10 centers across the country.
A novel, non-genetically modified form of a common 
cold virus, CVA21 targets a protein called ICAM that 
is highly expressed on the surfaces of many cancer cells. 
Once CVA21 attaches to ICAM, it can infect and kill 
cancer cells. In preclinical studies, the death of cancer 
cells induced by CVA21 primed the immune system 
to recognize and destroy malignancies, suggesting a 
potential synergy when it is combined with checkpoint 
inhibitors and other immunotherapies.Brendan D. Curti, M.D., member and director, Cytokine and Adoptive Immunotherapy 
Program, Genitourinary Oncology Research and Providence Melanoma Program, and
Walter J. Urba, M.D., Ph.D., member, director and endowed chair of Cancer Research
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In recent years, the number of treatments for 
patients with advanced melanoma has increased with 
the development of immune checkpoint inhibitors. 
However, not all patients respond to these therapies, 
and some patients who respond initially develop disease 
progression later. “These patients have few treatment 
options and a poor outlook,” said Dr. Curti. 
At the 2017 annual meeting of the American 
Association for Cancer Research, Dr. Curti presented 
early results, reporting better responses in patients who 
received the combination compared to patients who 
received either therapy given alone in prior studies. “A 
significant number of patients experienced regression of 
their cancers,” said Dr. Curti. “The CVA21-ipilimumab 
combination may represent a valuable treatment option 
for an unmet need in patients with advanced melanoma,” 
said Dr. Curti. 
CHECKPOINT-INDUCED TUMOR EVOLUTION
In another multicenter phase I study, Dr. Urba 
and colleagues evaluated the mechanisms by which 
checkpoint inhibition modulates tumor evolution in 
patients with advanced melanoma. 
As reported in the journal Cell, they observed changes 
in patients’ tumors in response to treatment with 
nivolumab, an anti-PD-1 checkpoint inhibitor. Through 
DNA, RNA and T-cell receptor sequencing, they found 
the tumor mutation burden – the number of mutations 
within a tumor genome – was reduced in responding 
tumors. A high tumor mutation burden is associated 
with an increase in neoantigens – proteins encoded by 
tumor-specific mutated genes which may serve as targets 
of checkpoint inhibitors. 
They also observed an increase in immune cell 
infiltration of responding tumors, and the expansion 
of specific T-cell clones. “T-cell clonal expansion 
accompanied by the loss of neoantigens suggests the 
development of an effective immune response,” said 
Dr. Urba. “These data have important implications for 
understanding the mechanisms of action of checkpoint 
inhibitors and for the design of future clinical trials.” 
ADOPTIVE CELL THERAPY
In collaboration with Loyola University, Dr. Curti 
engaged in a phase I study of adoptive cell therapy, or 
ACT, in patients with metastatic melanoma. Celebrated 
as the Advance of the Year by the American Society 
of Clinical Oncology, ACT harnesses the ability of 
the immune system to eliminate cancer through the 
collection, amplification and reinfusion of patients’ 
tumor-killing T cells. 
The investigators sought to enhance the tumor-killing 
potency of patients’ T cells through T-cell engineering. In 
the ongoing study, they tested the safety and effectiveness 
of T cells endowed with a new receptor capable of 
recognizing tyrosinase, an enzyme present in most 
melanoma cells. “The future of ACT will involve more 
sophisticated T-cell engineering,” said Dr. Curti. “We are 
at the forefront of these efforts.” Dr. Curti will continue 
his investigation of novel ACT in partnership with 
Eric Tran, Ph.D., assistant member, Antitumor T-cell 
Response Laboratory, whose lab is focused on identifying 
neoantigens with potential for targeting by ACT.
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A significant number of patients 
experienced regression of their cancers.
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Phase I Studies and  
Lung Cancer
Rachel E. Sanborn, M.D., oversees a robust 
phase I clinical trials portfolio of experimental 
cancer immunotherapies, targeted therapies 
and other novel agents. An expert in thoracic 
cancers, she leads numerous studies to improve 
outcomes for patients with lung cancer. 
PHASE I STUDY FOR ADVANCED CANCERS
At the 2017 annual meeting of the American Society 
of Clinical Oncology, Dr. Sanborn gave an oral 
abstract presentation on a phase I/II study investigating 
varlilumab, an immune-stimulating antibody, in 
combination with nivolumab, an anti-PD-1 checkpoint 
inhibitor approved for several cancers. 
Varlilumab targets and binds to CD27, a protein 
found on the surfaces of T cells, activating an anti-
cancer immune response. Investigators hypothesized the 
combination of varlilumab and nivolumab could have 
an additive benefit compared to the minimal response 
expected if patients were given nivolumab only.
The study aims to test the safety and anti-cancer 
activity of varlilumab in patients with advanced cancers 
that have resisted prior therapies, including melanoma 
and cancers of the colon, ovary, head and neck. Of 
nearly 20 sites participating throughout the country, Dr. 
Sanborn and colleagues at Providence Cancer Institute 
were the first investigators to enroll patients to the study.
Reporting preliminary results, Dr. Sanborn noted  
the combination was well-tolerated, and 14 of 36 
patients enrolled to the study saw their tumors shrink Rachel E. Sanborn, M.D., associate member, Phase I Clinical Trials Program, 
and co-director, Providence Thoracic Oncology Program
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or stabilize in response to therapy. These findings were 
significant, given the patients’ advanced state of disease 
and poor prognosis. 
“Combining PD-1 inhibition with a potent T-cell 
activating agent provides the opportunity to increase 
the number of patients that benefit from checkpoint 
immunotherapy,” said Dr. Sanborn. “While early, we have 
evidence that this combination does not add toxicity and 
may offer patients clinical benefit, particularly those who 
are unlikely to respond to other therapies.”
Based on the favorable results, investigators will 
evaluate various dose schedules to determine the optimal 
treatment regimen.
LUNG CANCER VACCINE PILOT STUDY
While immune checkpoint inhibitors have improved 
survival of patients with non-small cell lung cancer, 
or NSCLC, the disease remains the leading cause of 
cancer death worldwide. Strategies that increase immune 
recognition and control of NSCLC are needed. Vaccines 
present a promising approach to priming the immune 
system to recognize and destroy this deadly malignancy.
In collaboration with Bernard A. Fox, Ph.D., 
member and Harder Family Chair, Molecular and 
Tumor Immunology Laboratory, and Hong-Ming Hu, 
Ph.D., associate member, Cancer Immunobiology 
Laboratory, Dr. Sanborn conducted a pilot study to test 
the safety and clinical activity of a novel cancer vaccine 
in combination with docetaxel, a standard-of-care 
chemotherapy. 
With support from the National Cancer Institute 
and the Kuni Foundation, six patients with advanced 
NSCLC received intravenous infusion of docetaxel, 
followed by a cancer vaccine derived from their own 
tumor cells. The autologous vaccine, known as DRibbles, 
was created by Drs. Hu and Fox by isolating tumor cells 
from the study patients and processing the cells into 
a vaccine formulation in the laboratory. In preclinical 
studies, the vaccine demonstrated both protective and 
therapeutic anti-cancer immunity.
“The autologous DRibbles vaccine was safe in 
the small population of patients tested,” said Dr. 
Sanborn. Results were published in the Journal for 
ImmunoTherapy of Cancer, and further investigation 
of the DRibbles vaccine has moved forward with an off-
the-shelf, or allogeneic, formulation in development for 
patients with locally advanced NSCLC and other cancers.
INVESTIGATOR-INITIATED LUNG  
CANCER STUDY
Another study designed for patients with advanced 
NSCLC, Dr. Sanborn leads an investigator-initiated 
phase I/II clinical trial of pembrolizumab, another anti-
PD-1 checkpoint inhibitor approved for a variety of 
cancers, in combination with gemcitabine, a standard-of-
care chemotherapy. 
The study was also selected for presentation by the 
American Society of Clinical Oncology, where Dr. 
Sanborn reported a favorable safety profile among six 
patients. Approximately 16 patients are expected to 
participate in the trial, which is ongoing through the 
sponsorship of Providence Health & Services.
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Combining PD-1 inhibition with 
a potent T-cell activating agent 
provides the opportunity to increase 
the number of patients that benefit 
from checkpoint immunotherapy.
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Radiation Research
As physician scientists specializing in radiation 
oncology and immunotherapy, Marka R. 
Crittenden, M.D., Ph.D., and Kristina H. Young, 
M.D., Ph.D., seek to develop more effective 
treatments for patients with cancer.
INTEGRATING RADIATION AND 
IMMUNOTHERAPY
Drs. Crittenden and Young are active proponents of 
incorporating radiation oncology into immunotherapy. 
As members of the American Society for Radiation 
Oncology and the Society for Immunotherapy of Cancer, 
they were invited to attend the 2017 Immunotherapy 
Workshop, a joint meeting of the societies in 
collaboration with the National Cancer Institute.
Held in Washington, D.C., the workshop addressed 
important topics concerning the integration of these 
cancer therapies. Dr. Crittenden chaired a session 
on “Rational Combinations of Radiation with 
Immunotherapy,” which included colleagues from Johns 
Hopkins University, the University of Pennsylvania, and 
Stanford, while Dr. Young presented preliminary results of 
her phase II clinical trial testing a novel immunotherapy 
in combination with chemoradiation in patients with 
rectal cancer. The study, which includes Dr. Crittenden as 
a co-investigator, was also selected for presentation by the 
two societies at their 2017 annual meetings, and at the 
2017 Immuno-Oncology Young Investigators’ Forum. 
Learn more about this study on Pages 4 and 18.
ACT IV GLOBAL STUDY
Glioblastoma is the most common malignant primary 
brain tumor in adults. While cancers of the brain and 
Marka R. Crittenden, M.D., Ph.D., associate member, Integrated Therapies Laboratory,  
and director, Translational Radiation Research, and Kristina H. Young, M.D., Ph.D.,  
assistant member, Tumor Microenvironment Laboratory
36 LABORATORY RESEARCH: Antitumor T-cell Response Laboratory 37
nervous system account for less than two percent of 
new cancer diagnoses in the United States annually, 
glioblastoma is an aggressive cancer with poor prognosis: 
a mere 15 months is the typical length of survival  
after diagnosis. 
Researchers turned to immunotherapy as a potential 
approach to improve patient outcomes. An expert 
in radiation and immunotherapy for patients with 
glioblastoma, Dr. Crittenden engaged in a global, phase 
III clinical trial testing an experimental immunotherapy 
in this disease. With 165 centers in 22 countries 
participating, the randomized, double-blind study 
known as ACT IV is the most comprehensive of its kind.
Dr. Crittenden and colleagues evaluated the safety and 
effectiveness of rindopepimut, an investigational cancer 
vaccine, in combination with temozolomide, a standard-
of-care chemotherapy, in patients with newly diagnosed 
glioblastoma. Rindopepimut targets EGFRvIII, a protein 
arising from a mutation of the EGFR gene, which 
is expressed in up to 30 percent of glioblastomas. In 
previous trials, the vaccine extended patient survival by 
an average of nine months.
Of the 745 patients who enrolled, half received 
rindopepimut and half received a placebo; all patients 
received temozolomide. Only patients with EGFRvIII-
expressing glioblastomas were eligible, and all patients 
completed surgical resection and conventional 
chemoradiation prior to entering the study. 
As reported in The Lancet Oncology, the investigators 
found no significant difference between patients 
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who received the placebo and those who received the 
vaccine. “While disappointing, these results underscore 
the importance of well-controlled clinical trials in the 
development of new treatments for cancer,” said  
Dr. Crittenden. Investigators halted the study early,  
yet numerous clinical trials testing various EGFRvIII-
targeting strategies are ongoing in efforts to make 
progress against this formidable cancer.
RADIOTHERAPY AS IMMUNOTHERAPY
In other research, Dr. Crittenden is examining how 
the immunological effects of radiation therapy can be 
enhanced when immune-suppressing forces within 
the tumor microenvironment are rendered ineffective. 
In collaboration with Michael J. Gough, Ph.D., 
associate member, Integrated Therapies Laboratory, she 
is evaluating the role of a family of three cell-surface 
receptors, Tyro3, Axl, and Mertk – or TAM, in tumor 
immune suppression. 
Studies show the activity of Axl and Mertk in the 
tumor microenvironment prevents an effective anti-
cancer immune response. Studies also demonstrated the 
efficacy of radiation in eradicating tumors, and directing 
anti-cancer immune responses toward residual cancer 
cells found at the tumor site and throughout  
the body. 
In Emerging Topics in Life Sciences, Drs. Crittenden 
and Gough report how the potential synergy of radiation 
therapy with the loss or blockade of these receptors 
could facilitate immune activation. “Inhibition of the 
TAM family members is a potent therapeutic strategy to 
initiate immune responses following radiation-induced 
cancer cell death,” said Dr. Crittenden. Learn more about 
the Integrated Therapies Lab on Page 14.
These results underscore the importance 
of well-controlled clinical trials in the 
development of new treatments for cancer.
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STATE-OF-THE-ART SERVICES
With 45,000 square feet dedicated to cancer research, the Earle A. 
Chiles Research Institute is home to several core facilities, offering our 
investigators and collaborators the latest in immunological monitoring, 
flow cytometry, immunohistochemistry, molecular pathology and 
bioinformatics services.
BIOSPECIMEN REPOSITORY
For more than 20 years, we have maintained a Biospecimen Repository of malignant 
and benign tissues donated by more than 1,000 patients. Containing more than 60,000 
samples, nearly 80 types of cancer are represented from which our scientists perform 
ongoing, novel research.
IMMUNE MONITORING LABORATORY
Our Immune Monitoring Laboratory is the archival and disbursement center for the 
acquisition, processing, cryopreservation and cataloguing of all tumor tissue, peripheral 
blood mononuclear cells and serum collected during the course of cancer clinical trials. 
Together with the Flow Cytometry Core, the IML is a national leader in developing 
and implementing immune monitoring assays for the evaluation of anti-tumor immune 
responses in cancer patients receiving immunotherapy.
FLOW CYTOMETRY CORE
A heavily used and valuable resource, our Flow Cytometry Core allows investigators 
to refine their immunotherapy strategies by measuring anti-tumor immune responses 
on a cellular level. A component of the IML, the core is equipped with a BD Fortessa, 
BD LSRII, Beckman Coulter Cytoflex, BD FACS Aria II Cell Sorter with BSL2 
Containment System, BD FACS Calibur, CTL ImmunoSpot ELISpot, Luminex  
Bio-Plex 100 and Guava PCA-96, among other instruments. 
IMMUNO-HISTOLOGY CORE
Established in 2017 as a component of the IML, the Immuno-Histology Core performs 
advanced tissue and image analyses in support of our preclinical and clinical studies. It 
contains a Vectra 3.0 Automated Quantitative Pathology Imaging System; a Zeiss Z1 
Motorized Stage Fluorescence Microscope; a Sakura Tissue-Tek, Leica Embedder and 
RM2235 Rotary Microtome for tissue processing, embedding and sectioning; Ventana 
Discovery Ultra and Leica auto strainers; and a TMA Master for tissue microarray. 
MOLECULAR PATHOLOGY CORE
A fundamental component of our translational research, the Molecular Pathology Core 
provides investigators with molecular correlates to their research questions, enabling the 
measurement of high-throughput omics projects with clinically validated bioinformatics 
pipelines. Services include next-generation sequencing of whole exomes and RNA, 
the analysis and quantification of circulating tumor DNA, mutation analysis with 
neoantigen prediction and NanoString technology, and T-cell receptor analysis, among 
other services.
Our newest core facility, the Immuno-Histology Core provides investigators  
at Providence Cancer Institute with advanced immunohistochemistry services.
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TRAINING PROGRAMS
As part of our mission to train the next generation of immunologists, 
the Earle A. Chiles Research Institute offers a rich training environment 
with programs spanning the continuum of higher education, from 
undergraduates to postdoctoral fellows.
SUMMER RESEARCH PROGRAM. An intensive nine-week internship for 
undergraduate students, this program provides hands-on research experience and 
mentorship for students pursuing careers in biomedical sciences. Interns complete  
an independent research project and present their results at a capstone poster session.  
They receive training in bioinformatics, and attend research seminars and meetings  
where recent journal articles are reviewed and discussed. Past interns have been accepted 
to the Mayo Clinic Graduate School of Biomedical Sciences, Northwestern University 
School of Medicine and Oregon Health & Science University School of Medicine. 
GRADUATE EDUCATION. Through partnerships with OHSU and universities 
in China, graduate students conduct laboratory research under the guidance of our 
faculty members with university appointments. Students have opportunities to give 
poster presentations at national conferences and present their research at department 
seminars while advancing to doctoral candidacy. Previous students have been accepted 
to postdoctoral fellowships at the National Cancer Institute, INSERM (French National 
Institute of Health and Medical Research) and within the biotechnology industry.
POSTDOCTORAL TRAINING. Seeking to acquire the professional skills and 
experience necessary for independent scientific careers, fellows are mentored in cancer 
immunotherapy expertise, research skill development, leadership, communication 
and the responsible conduct of research. The pursuit of external funding and a strong 
publication record are hallmarks of the program. Previous fellows have received  
funding from the NIH Pathway to Independence Award, the American Cancer Society,  
Susan G. Komen and the Prostate Cancer Foundation, and obtained appointments  
at Rush University, Legacy Research Institute and OHSU.
PHOTO ABOVE RIGHT: 2017 Summer Research Program interns. RIGHT: Interns 
present their research projects at a capstone poster session.
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BREAKTHROUGH TREATMENTS. TRANSFORMATIVE CARE.
Providence Cancer Institute offers patients the unique 
advantages of both a world-class cancer research institute and a patient-
centered community cancer program. From powerful, breakthrough 
treatments to compassionate, transformative care and support, we 
surround patients with everything they need for recovery and healing.
Unmatched experience, more clinical trials,  
superior outcomes
Studies show that patients do better in centers that treat more people. Our experience 
supports that:
n	 Providence Cancer Institute diagnoses and treats more people with cancer  
than any other health system in the Portland area. 
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The Providence patient groups include all patients diagnosed with breast cancer from  
2008-2014 who received all or part of their initial course of treatment at Providence Cancer 
Institute. SEER relative survival rates used for comparison are also for patients diagnosed from 
2008-2014 and follow-up of patients into 2015. Survival rates have not been adjusted for 
age, gender, race/ethnicity or insurance status.
n Providence patients have greater access to promising new treatment options. 
In 2017, more than 245 cancer research studies 
were open to our patients, including 170 therapeutic 
clinical trials and 48 phase I trials. More than 30 percent 
of our adult patients participated in cancer research 
studies, compared to 2 to 4 percent nationally.
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Compassionate support
In addition to powerful cancer therapies, we offer supportive care for  
the body, mind and spirit. Providence patients have access to:
n Nurse navigators to guide them through their experiences
n Integrative care: acupuncture, naturopathy and massage therapy 
n Social work services, including 1:1 counseling and in-person or  
online English and Spanish support groups
n Nutrition advice from registered oncology dietitians
n Palliative care
n Financial counseling
n Extensive resources online at ProvidenceOregon.org/cancersupport
In 2017, we also produced a new series of videos to provide patients with 
practical advice for coping with the common side effects of cancer and its 
treatment. The videos feature Providence patients and providers, and can  
be seen at ProvidenceOregon.org/livingwellvideos.
599 head and neck 
cancer screenings 
Learn more about our clinics, services and events at ProvidenceOregon.org/cancer.
We also helped raise cancer awareness throughout the state by hosting  
and participating in 33 community events in 2017.
Prevention and outreach
Providence Cancer Institute provided  
cancer screenings to hundreds of 
Oregonians in 2017 through outreach 
programs aimed at detecting cancer in the 
earliest stages, when it is most treatable.
Lung cancer screenings: 
678 new patients screened
1,430 total scans 
28 cancers found 
160 skin cancer  
screenings  
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A Portland native, Robert W. “Bob” Franz became a  
passionate supporter of research to end cancer in 1986 
when he joined the board of Providence Portland 
Medical Foundation. His intense curiosity, generosity and 
leadership played a major role in launching and furthering 
cancer research efforts at Providence Portland Medical 
Center, the future home of Providence Cancer Center.
EARLY SUPPORTER
Bob and his sister Elsie Franz Finley were early supporters 
of Providence Cancer Center and its trailblazing successes 
in the field of immunotherapy. Together, Bob and Elsie 
quietly and consistently ensured Providence researchers 
had the resources they needed to become international 
leaders in immunotherapy for patients with cancer.
Immunotherapy boosts the body’s own defenses 
against cancer by activating the immune system to find 
and destroy tumors. This approach has been shown to be 
effective in several types of advanced cancers, including 
lung, bladder, lymphoma and kidney cancers, as well  
as melanoma.  
TRANSFORMATIONAL PHILANTHROPIST
With a lifetime of philanthropic support for cancer 
research, Bob’s total giving to Providence Portland 
Medical Foundation – $40 million – makes him the 
single largest donor in Providence’s 142 years in Oregon. 
Bob died in August 2016 and as a fitting and 
lasting tribute to him and his legacy of contributions, 
Providence Cancer Center – the 11-story tower that 
houses cancer research and services – was renamed in  
Robert W. Franz Cancer Center named to honor Oregon philanthropist
and research space, and speed progress toward Providence’s 
overarching goal to finish cancer in our lifetimes. 
“Bob’s gift is transformative,” said Walter J. Urba, 
M.D., Ph.D., member, director and endowed chair of 
Cancer Research at the Earle A. Chiles Research Institute, 
the research arm of the Robert W. Franz Cancer Center. 
“It allows us to think about the future in ways we never 
have before. With the support of Providence and people 
like Bob, our team is well-positioned to show just how 
potent immunotherapy can be in the treatment of cancer.”
A commemorative plaque depicting the transformational philanthropy of Robert W. 
Franz greets patients and guests entering the cancer center named in his honor. 
With the support of Providence and 
people like Bob, our team is well-
positioned to show just how potent 
immunotherapy can be in the  
treatment of cancer.
his honor in October 2017. The facility is now the 
Robert W. Franz Cancer Center, part of Providence 
Cancer Institute.
The Franz estate gift will be used to attract more top 
researchers from around the world, build new laboratory 
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Hood to Coast
The 2017 Providence Hood to Coast Relay was a huge success, raising more than 
$740,000 for cancer research at Providence. This is the fifth year the relay has been a 
major fundraiser for Providence. Teams that fundraise are guaranteed one of the coveted 
spots in the race. The top fundraising team for 2017 was All In, No Regrets. They raised 
$42,495 for cancer research.
More than 1,000 running teams participated in the 199-mile race from Mt. Hood 
to the coastal town of Seaside, Oregon. An additional 400 walking teams and 50 high 
school teams covered the 130-mile Portland to Coast Relay.
Creating Hope
Research creates new treatments and new treatments create hope. That was the message 
to the more than 500 supporters of Providence Cancer Institute who attended the 
Providence Creating Hope Dinner on May 24, 2017. 
The 19th annual Creating Hope dinner broke records, raising more than $778,000 
in support of cancer research. Coupled with contributions from Safeway customers and 
employees throughout the month of May, more than $1 million was raised for 
translational cancer research. 
The signature fundraising event for cancer research featured Diane Davis, a survivor of 
ovarian cancer thanks to lifesaving immunotherapy she received as part of a first-in-
human clinical trial at Providence. Guests also heard from Bernard A. Fox, Ph.D., and 
Eric Tran, Ph.D., faculty members of the Earle A. Chiles Research Institute, on the 
importance of philanthropy in advancing treatments for cancer patients.
Team Runners4Research includes Providence Cancer Institute scientists, nurses,  
doctors and friends.
ABOVE: Drs. Tran and Fox talk with emcee Helen 
Raptis, thanking Providence donors for their 
generous support. INSET: With her husband Jim, 
Diane Davis shares why she is a cancer survivor 
thanks to immunotherapy treatment and research 
at Providence. 
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F CTS & FIGURES
BY THE NUMBERS: 2017 FACTS AND FIGURES
Investigators & Personnel
19 faculty members
49 clinical researchers
63 lab researchers
Grant Funding, Sponsored  
Research & Philanthropy
$4.5 million annually in  
federal, private and sponsored  
research funding
$32.5 million raised by  
Providence Foundations in Oregon  
for Providence Cancer Institute
Memberships & Collaborations
•	 Bristol	Myers-Squibb	
International Immuno-Oncology 
Network
•	 NCI	Community	Oncology	
Research Program via Pacific 
Cancer Research Consortium
•	 NCI	Cancer	Immunotherapy	 
Trials Network
•	 Partnership	with	MedImmune/
AstraZeneca for clinical 
development of anti-OX40
Institute Publications
142 total publications:
53 journal articles
10 books and book chapters
79 conference abstracts
Clinical Trials
246 cancer clinical trials open  
for enrollment, including 
170 therapeutic trials and  
48 phase I trials
1,798 total enrollments
INVITED SEMINARS 
l 13 visiting professor seminars
l
	 78 faculty extramural seminars 
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Faculty Members
R. Bryan Bell, M.D., D.D.S., FACS
Assistant member and medical director, 
Providence Head and Neck Cancer 
Program and Clinic
Head and Neck Oncologic Surgery
Carlo B. Bifulco, M.D.  
Member and director,  
Translational Molecular Pathology   
Medical director, Molecular Genomics   
Anatomic and Molecular Pathology 
Alison K. Conlin, M.D., MPH
Associate member and medical director, 
Providence Breast Cancer Medical 
Program and High-Risk Breast Clinic
Medical Oncology
Marka R. Crittenden, M.D., Ph.D.
Associate member,  
Integrated Therapies Laboratory
Director, Translational Radiation Research
Radiation Oncology
Todd S. Crocenzi, M.D.  
Associate member and director,  
Gastrointestinal Oncology Research  
Medical Oncology
Brendan D. Curti, M.D.
Member and director,
Cytokine and Adoptive Immunotherapy 
Program, Genitourinary Oncology 
Research and Providence Melanoma 
Program
Medical Oncology
Bernard A. Fox, Ph.D.
Member and Harder Family Endowed 
Chair for Cancer Research, Molecular  
and Tumor Immunology Laboratory
John E. Godwin, M.D., MS  
Member and program leader,  
Hematologic Malignancies   
Medical Oncology 
Michael J. Gough, Ph.D.
Associate member,  
Integrated Therapies Laboratory
Hong-Ming Hu, Ph.D.  
Associate member,  
Cancer Immunobiology Laboratory 
Rom S. Leidner, M.D.
Assistant member and co-director, 
Providence Head and Neck Cancer 
Program
Medical Oncology
Philippa H. Newell, M.D.  
Assistant member and medical director,  
Providence Liver Cancer Clinic  
Liver and Pancreas Surgery
David B. Page, M.D.  
Assistant member,  
Breast Cancer Immunotherapy  
Medical Oncology 
William L. Redmond, Ph.D.  
Associate member,  
Cancer Immunotherapy Laboratory  
Director, Immune Monitoring Laboratory 
Franz Leadership Cabinet 
The Robert W. Franz Cancer Leadership 
Cabinet comprises men and women 
with a desire to connect the Portland 
metropolitan community with the 
dedicated teams of researchers working 
to finish cancer at the Earle A. Chiles 
Research Institute. Founded in 2001, the 
leadership cabinet has a strong and loyal 
membership representing a broad 
spectrum of the community. 
2017 CABINET MEMBERS
TJ O’Connor, chair
Flo Atkinson
Stephen Bader, M.D.
Mark Beckius
Walter C. Bowen
Kay Carlisle
Charlie Engelberg
Dan Floyd
Pedro Garcia
Diana Hall
Cindy Harder
Dan Kinney
Sheryl Langerman Rosenfeld
Lynn Loacker
Patricia Markesino
Nicole McIntyre
Jooyon K. “Julieann” Park
Linda Read
James F. Robb, Ph.D.
Linda Smiley
Mark Williams
Linda Yoshida
Rachel E. Sanborn, M.D.  
Associate member,  
Phase I Clinical Trials Program  
Co-director, Providence Thoracic 
Oncology Program   
Medical Oncology 
Eric Tran, Ph.D.  
Assistant member,  
Antitumor T-cell Response Laboratory 
Walter J. Urba, M.D., Ph.D.
Member, director and endowed chair  
of Cancer Research
Medical Oncology
Andrew D. Weinberg, Ph.D.  
Member and Judith Ann Hartmann 
Endowed Chair for the Laboratory  
of Basic Immunology  
Kristina H. Young, M.D., Ph.D.  
Assistant member,  
Tumor Microenvironment Laboratory  
Radiation Oncology
Administration
Julie Cramer, MA, CCRP
Administrative director,  
Cancer Clinical Research
Samantha Kaiser
Director, Cancer Research Operations
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OUR MISSION
As expressions of God’s healing love,  
witnessed through the ministry of Jesus, 
we are steadfast in serving all, especially 
those who are poor and vulnerable.
OUR VALUES
Compassion, Dignity, Justice
Excellence, Integrity
chilesresearch.org 
